NVX102

NVX102 (also known as AMD101 Improved Topical Product) is a preclinical-stage topical ophthalmic product being developed by NeoVascularX for the treatment of age-related macular degeneration (AMD). It is designed as a next-generation or improved version of the company's flagship product, NVX101, with the goal of enhancing efficacy and patient convenience. Administered as a topical eye drop, NVX102 aims to provide a non-invasive alternative to the standard-of-care intravitreal injections for neovascular AMD by delivering the active agent efficiently to sub-retinal tissues. The specific molecular target and mechanism of action have not been publicly disclosed, though the product is part of a pipeline focused on non-invasive delivery to sub-retinal tissue.